A5053343957- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Ferroptosis and cancer prognosis
- Cancer-related molecular mechanisms research
- Fungal Infections and Studies
- Acne and Rosacea Treatments and Effects
- Asthma and respiratory diseases
- Skin Protection and Aging
- Dermatologic Treatments and Research
- Urticaria and Related Conditions
- Mycobacterium research and diagnosis
- Psoriasis: Treatment and Pathogenesis
- melanin and skin pigmentation
- Food Allergy and Anaphylaxis Research
- Antifungal resistance and susceptibility
- Cervical Cancer and HPV Research
- Autoimmune Bullous Skin Diseases
- Infectious Diseases and Tuberculosis
- Epigenetics and DNA Methylation
- Syphilis Diagnosis and Treatment
- Systemic Lupus Erythematosus Research
- Reproductive tract infections research
- Nonmelanoma Skin Cancer Studies
- MicroRNA in disease regulation
- Cutaneous lymphoproliferative disorders research
Hangzhou Medical College
2017-2025
Zhejiang Provincial People's Hospital
2016-2025
Nanchang University
2013-2025
Jiangxi Chest Hospital
2016-2024
Zhejiang University
2023
Beijing University of Chinese Medicine
2012-2022
Zhejiang Hospital
2021
Guilin University of Technology
2020
Shandong University of Finance and Economics
2012
Shenzhen Chronic Disease Prevention Center
2010
Abstract Background: Atopic dermatitis (AD) affects approximately 10% of adults worldwide. CM310 is a humanized monoclonal antibody targeting interleukin-4 receptor alpha that blocks and interleukin-13 signaling. This trial aimed to evaluate the efficacy safety in Chinese with moderate-to-severe AD. Methods: multicenter, randomized, double-blind, placebo-controlled, phase 2b was conducted 21 medical institutions China from February November 2021. Totally 120 eligible patients were enrolled...
Background: Mucous membrane pemphigoid (MMP), a rare autoimmune vesiculous and erosive disorder, may affect multiple mucous membranes, with the oral cavity being most commonly affected site. Its treatment depends on site(s) of mucosal involvement disease severity. Patients Methods: A 62-year-old female patient MMP that predominantly involved strongly rejected systemic corticosteroid or immunosuppressive agents was successfully treated abrocitinib, highly selective JAK-1 inhibitor good safety...
Abstract Atopic dermatitis is a chronic inflammatory skin disease with significant impact on the overall wellbeing of patients and their families. Crisaborole ointment, 2%, nonsteroidal phosphodiesterase 4 inhibitor approved for treatment mild‐to‐moderate atopic in multiple countries. However, key pivotal trials, low proportion patient population was Asian, therefore safety efficacy crisaborole Asian remains unclear. CrisADe CLEAR multicenter, randomized, double‐blind, vehicle‐controlled,...
Abstract Background Management of moderate‐to‐severe atopic dermatitis (AD) needs long‐term therapy. Stapokibart is a humanized monoclonal antibody targeting interleukin‐4 receptor α subunit (IL‐4Rα), shared for IL‐4 and IL‐13 which are key pathogenic drivers AD. In pivotal phase 3 trial (NCT05265923), significant higher proportions adult AD patients receiving stapokibart than placebo achieved ≥75% improvement from baseline in Eczema Area Severity Index (EASI‐75; 66.9% vs. 25.8%)...
Abstract Ferroptosis, a type of programmed cell death, occurs when there is oxidative stress and lipid peroxides. This condition marked by peroxidation that relies on iron the reduction cellular defences against oxidation. To investigate effect UVB irradiation ferroptosis human keratinocytes HaCaT cells, cells were pretreated with Ferrostatin 1 (Fer‐1, 10 μM), an inhibitor then irradiated (20 mJ/cm 2 ) for 30 min to detect related indexes through MTT assay, quantitative real‐time polymerase...
JS005 is a novel anti-IL-17A monoclonal antibody. A Phase Ia study (Study 1) in healthy adults, followed by Ib/II 2) patients with moderate to severe plaque psoriasis (PsO), were designed evaluate the safety, efficacy, and pharmacokinetic characteristics of JS005. Study 1 was double-blind, randomized, placebo-controlled, single dose-escalation (15, 60, 150, 300, 600 mg) study. Forty participants enrolled. 2 consisted (60, or phase Ib, multicentre, placebo-controlled II administering 300 mg,...
Abstract: Background: Stapokibart has been approved for the treatment of adults with atopic dermatitis (AD) in China.